Human Relaxin-2 Quantikine ELISA Kit

• Reactivity: Hu
• Applications: ELISA
• Conjugate: HRP

Human Relaxin-2 Quantikine ELISA Kit Summary

• Background: The Quantikine Human Relaxin-2 Immunoassay is a 4.5 hour solid phase ELISA designed to measure human Relaxin-2 in cell culture supernates, serum, and plasma. It contains E. coli-expressed recombinant human Relaxin-2 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human Relaxin-2 showed linear curves that were parallel to the standar...d curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human Relaxin-2.
  Show More
• Specificity: Natural and recombinant human Relaxin-2
• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: RLN2

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human Relaxin-2 Quantikine ELISA Kit

• bA12D24.1.1
• bA12D24.1.2
• H2
• relaxin 2
• Relaxin2
• Relaxin-2
• RLN2
• RLXH2

Background

The Insulin/Relaxin superfamily includes Insulin, IGF-I, IGF-II, Relaxins, Relaxin-like Factor (RLF), Early Placenta Insulin-like Peptide 4 (INSL4), INSL5, and INSL6. Three human Relaxin genes (Relaxins-1 to -3) have been identified. Relaxin-2 is secreted and circulates in the blood, whereas Relaxin-1 is expressed in decidua, placenta, and prostate, and Relaxin-3 is expressed in the brain. Human Relaxin-2 is a peptide hormone that plays an important role in female reproduction.

⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Publications for Relaxin-2 (DRL200)(13)

Publications using DRL200

• MVC Rudge, FP Souza, JF Abbade, RLS Hallur, JPC Marcondes, F Piculo, G Marini, G Vesentini, L Thabane, SS Witkin, IMP Calderon, AMP Barbosa, MV Rudge, AMP Barbosa, IMP Calderon, FP Souza, JF Abbade, LSR Hallur, F Piculo, G Marini, G Vesentini, L Thabane, MS Palma, CFO Graeff, RK Arni, RD Herculano, DF Salvadori, S Mateus, M Dal Pai Si, CG Magalhães, RA Costa, SAM Lima, SL Felisbino, W Barbosa, A Atallah, MJB Girão, Z Di Bella, SM Uchoa, S Payão, A Hijas, B Berghman, R De Bie, L Sobrevia, B Junginger, FCB Alves, PS Rossignoli, CB Prudencio, MIG Orlandi, MI Gonçalves, SK Nunes, BB Catinelli, S Quiroz, BV Sarmento, FA Pinheiro, CI Sartorão, RR Lucas, DRA Reyes, SBCV Quiroz, EMA Enriquez, RG Oliveira, JF Floriano, JPC Marcondes, S Barneze, TD Dangió, T Pascon, P Rossignoli, JV Freitas, L Takano, F Reis, TD Caldeirão, JN Fernandes, AM Carr, MVC Gaitero, JE Corrente, HRC Nunes, AF Candido, SMB Costa, TD Dangió, T Pascon, JVF Melo, L Takano, FVDS Reis, TD Caldeirão, AM Carr, GA Garcia, GB Rabadan, HCM Bassin, KS Suyama, LN Damasceno, MLS Takemoto, MD Menezes, DG Bussaneli, VKC Nogueira, PR Lima, IO Lourenço, J Marostica, RA Megid, IP Caruso, LT Rasmussen, GM Prata, F Piculo, G Vesentini, MA Arantes, GAR Ferraz, LP Camargo, MR Kron, JE Corrente, HRC Nunes Study protocol to investigate biomolecular muscle profile as predictors of long-term urinary incontinence in women with gestational diabetes mellitus BMC Pregnancy Childbirth, 2020-02-19;20(1):117. 2020-02-19 [PMID: 32075598] (Human)
• T Lapinskas, S Kelle, J Grune, A Foryst-Lud, H Meyborg, S Jeuthe, E Wellnhofer, A Elsanhoury, B Pieske, R Gebker, U Kintscher, P Stawowy Serelaxin Improves Regional Myocardial Function in Experimental Heart Failure: An In Vivo Cardiac Magnetic Resonance Study J Am Heart Assoc, 2020-01-31;9(3):e013702. 2020-01-31 [PMID: 32000566] (Mouse)
• B Martin, B Gabris, AF Barakat, BL Henry, M Giannini, RP Reddy, X Wang, G Romero, G Salama Relaxin reverses maladaptive remodeling of the aged heart through Wnt-signaling Sci Rep, 2019-12-06;9(1):18545. 2019-12-06 [PMID: 31811156] (Rat)
• J Simon, E Nemeth, A Nemes, M Husveth-To, T Radovits, G Foldes, L Kiss, Z Bagyura, J Skopal, B Merkely, E Gara Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF Front Physiol, 2019-06-04;10(0):690. 2019-06-04 [PMID: 31231242] (Human)
• JA Luetkens, AC Wolpers, T Beiert, D Kuetting, D Dabir, R Homsi, H Meenderman, NA Dayé, V Knappe, M Karsdal, SH Nielsen, F Genovese, F Stöckigt, M Linhart, D Thomas, G Nickenig, HH Schild, JW Schrickel, RP Andrié Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy Sci Rep, 2018-09-11;8(1):13618. 2018-09-11 [PMID: 30206274] (Human)
• K Papoutsis, A Kapelouzou, DI Tsilimigra, N Patelis, G Kouvelos, D Schizas, I Karavokyro, S Georgopoul Associations between serum relaxin 2, aneurysm formation/size and severity of atherosclerosis: a preliminary prospective analysis Acta Pharmacol. Sin., 2018-03-22;0(0):. 2018-03-22 [PMID: 29565035] (Human)
• M Jelinic, CH Leo, SA Marshall, SN Senadheera, LJ Parry, M Tare Short-term (48 hours) intravenous serelaxin infusion has no effect on myogenic tone or vascular remodeling in rat mesenteric arteries Microcirculation, 2017-08-01;0(0):. 2017-08-01 [PMID: 28370794] (Rat)
• VK Snowdon, NJ Lachlan, AM Hoy, PW Hadoke, SI Semple, D Patel, W Mungall, TJ Kendall, A Thomson, RJ Lennen, MA Jansen, CM Moran, A Pellicoro, P Ramachandr, I Shaw, RL Aucott, T Severin, R Saini, J Pak, D Yates, N Dongre, JS Duffield, DJ Webb, JP Iredale, PC Hayes, JA Fallowfiel Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial PLoS Med, 2017-02-28;14(2):e1002248. 2017-02-28 [PMID: 28245243] (Human, Rat)
• J Valle Rale, AG Mauro, T Devarakond, C Marchetti, J He, E Kim, S Filippone, A Das, S Toldo, A Abbate, FN Salloum Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism Cardiovasc. Res, 2017-05-01;0(0):. 2017-05-01 [PMID: 28073832] (Human)
• HH Ng, CH Leo, D Prakoso, C Qin, RH Ritchie, LJ Parry Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes Sci Rep, 2017-01-09;7(0):39604. 2017-01-09 [PMID: 28067255] (Mouse)
• Jelinic M, Leo C, Post Uiterweer E, Sandow S, Gooi J, Wlodek M, Conrad K, Parkington H, Tare M, Parry L Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J, 2013-09-13;28(1):275-87. 2013-09-13 [PMID: 24036884] (Rat)
• Soh , Yu May, Tiwari , Anjana, Mahendroo , Mala, Conrad , Kirk P, Parry , Laura J Relaxin regulates hyaluronan synthesis and aquaporins in the cervix of late pregnant mice. Endocrinology, 2012-10-19;153(12):6054-64. 2012-10-19 [PMID: 23087172] (Human)
• Anumba DO, El Gelany S, Elliott SL Serum relaxin levels are reduced in pregnant women with a history of recurrent miscarriage, and correlate with maternal uterine artery Doppler indices in first trimester. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009-08-19;147(1):41-5. 2009-08-19 [PMID: 19695764] (Human)

Bioinformatics

• Gene Symbol: RLN2